Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 401 - 425 of 9454 in total
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Description: … life of patients and caregivers. ... treat manic episodes in bipolar disorder although the mechanism of action is unknown. ... several treatment options for psychotic disorders have been introduced to market since the realization of
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Categories: … Sex Hormones and Modulators of the Genital System …
Matched Products: … GESTRIL(R) …
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of ... [T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms ... reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated ... [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients ... (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of
Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. Patients with cTTP...
Approved
Investigational
Matched Description: … all cases of TTP. ... disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of ... cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia. ... [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- …
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Synonyms: … (+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine ... (+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine …
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in...
Approved
Matched Synonyms: … (R)-(−)-quinine ... (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol …
Matched Iupac: … (R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol …
Matched Description: … An alkaloid derived from the bark of the cinchona tree. ... The mechanisms of its antimalarial effects are not well understood. ... It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have …
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Synonyms: … (1r,2r,1'r,2'r)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7 …
Matched Description: … [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times ... [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release. …
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate ... [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone …
Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated falciparum malaria...
Approved
Investigational
Matched Description: … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin ... Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites ... Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum …
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … , Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … are synthetic structural analogs of prostaglandin. ... Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which …
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia,...
Approved
Matched Synonyms: … r-metHuLeptin …
Matched Description: … of adipose tissue. ... [L41315] Administration of metreleptin results in improvement of metabolic symptoms including improvements ... of leptin deficiency in people with lipodystrophy. …
Rumex acetosella pollen is the pollen of the Rumex acetosella plant. Rumex acetosella pollen is mainly used in allergenic testing.
Approved
Matched Description: … Rumex acetosella pollen is the pollen of the Rumex acetosella plant. …
Rumex altissimus pollen is the pollen of the Rumex altissimus plant. Rumex altissimus pollen is mainly used in allergenic testing.
Approved
Matched Description: … Rumex altissimus pollen is the pollen of the Rumex altissimus plant. …
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, …
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Matched Products: … ENTOCORT(R)2 MG ... RHINOCORT (R) AQUA 64 MCG/DOSIS …
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Displaying drugs 401 - 425 of 9454 in total